{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:18:13Z","timestamp":1792196293694,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,5,16]],"date-time":"2011-05-16T00:00:00Z","timestamp":1305504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1472-6963-11-101","type":"journal-article","created":{"date-parts":[[2011,5,18]],"date-time":"2011-05-18T02:23:18Z","timestamp":1305685398000},"source":"Crossref","is-referenced-by-count":74,"title":["Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barr\u00e9 syndrome"],"prefix":"10.1186","volume":"11","author":[{"given":"Jeffrey L","family":"Winters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Hazard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Chainani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Chester","family":"Andrzejewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,16]]},"reference":[{"key":"1637_CR1","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1056\/NEJM199204233261706","volume":"326","author":"AH Ropper","year":"1992","unstructured":"Ropper AH: The Guillain-Barr\u00e9 syndrome. New Engl J Med. 1992, 326: 1130-1136. 10.1056\/NEJM199204233261706.","journal-title":"New Engl J Med"},{"key":"1637_CR2","doi-asserted-by":"crossref","unstructured":"The utility of therapeutic plasmapheresis for neurological disorders. JAMA. 1986, NIH Consensus Development, 256: 1333-1337.","DOI":"10.1001\/jama.256.10.1333"},{"key":"1637_CR3","doi-asserted-by":"crossref","unstructured":"Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barr\u00e9 syndrome. Plasma Exchange\/Sandoglobulin Guillain-Barr\u00e9 Syndrome Trial Group. Lancet. 1997, 349: 225-230.","DOI":"10.1016\/S0140-6736(96)09095-2"},{"key":"1637_CR4","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1093\/brain\/awm004","volume":"130","author":"RA Hughes","year":"2007","unstructured":"Hughes RA, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn PA: Immunotherapy for Guillain-Barr\u00e9 syndrome: a systematic review. Brain. 2007, 130: 2245-2257. 10.1093\/brain\/awm004.","journal-title":"Brain"},{"key":"1637_CR5","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1212\/WNL.61.6.736","volume":"61","author":"RA Hughes","year":"2003","unstructured":"Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, Meythaler JM, Miller RG, Sladky JT, Stevens JC: Practice parameter: immunotherapy for Guillain-Barr\u00e9 syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003, 61: 736-740.","journal-title":"Neurology"},{"key":"1637_CR6","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","volume":"326","author":"FG van der Mech\u00e9","year":"1992","unstructured":"van der Mech\u00e9 FG, Schmitz PI: A randomized trail comparing intravenous immune globulin and plasma exchange in Guillain-Barr\u00e9 syndrome. Dutch Guillain-Barr\u00e9 Study Group. N Engl J Med. 1992, 326: 1123-1129. 10.1056\/NEJM199204233261705.","journal-title":"N Engl J Med"},{"key":"1637_CR7","doi-asserted-by":"crossref","unstructured":"Hughes RAC, Swan AV, van Doorn PA: Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome (review). Cochrane Database Syst Rev. 2006, CD002063-1","DOI":"10.1002\/14651858.CD002063.pub3"},{"key":"1637_CR8","unstructured":"U.S. Department of Health and Human Services. Analysis of Supply, Distribution, Demand, and Access Issues Associated with Immune Globulin Intravenous (IGIV). Final Report. 2007, [\n                    http:\/\/aspe.hhs.gov\/sp\/reports\/2007\/IGIV\n                    \n                  ]"},{"key":"1637_CR9","unstructured":"Florida Hospital IVIG Triage Plan, Florida Hospital, Department of Pharmacy. 2002, [\n                    http:\/\/www.ashp.org\/s_ashp\/docs\/files\/DShort_IVIGTriagePlan.doc\n                    \n                  ]"},{"key":"1637_CR10","unstructured":"Public Meeting on Patient and Physician Concerns in Access to Intravenous Immunoglobulin (IVIG). 2006, [\n                    http:\/\/www.hhs.gov\/bloodsafety\/TownHallTranscript.txt\n                    \n                  ]"},{"key":"1637_CR11","unstructured":"IV Immune Globulin Shortage Update. 2005, [\n                    http:\/\/www.ashp.org\/s_ashp\/docs\/files\/DShort_IVIGShortageUpdateSept05.doc\n                    \n                  ]"},{"key":"1637_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/jca.20240","volume":"25","author":"ZM Szczepiorkowski","year":"2010","unstructured":"Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH: Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apheresis. 2010, 25: 83-177. 10.1002\/jca.20240.","journal-title":"J Clin Apheresis"},{"key":"1637_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/ana.410410304","volume":"41","author":"French Cooperative Group on Plasma Exchange in Guillain-Barr\u00e9 Syndrome","year":"1997","unstructured":"French Cooperative Group on Plasma Exchange in Guillain-Barr\u00e9 Syndrome: Appropriate number of plasma exchanges in Gullian-Barr\u00e9 Syndrome. Ann Neurol. 1997, 41: 298-306.","journal-title":"Ann Neurol"},{"key":"1637_CR14","unstructured":"Centers for Medicare & Medicaid Physician Fee Schedule. [\n                    http:\/\/www.cms.hhs.gov\/physicianfeesched\/downloads\/2010_FINAL_DIRECT_PE.zip\n                    \n                  ]"},{"key":"1637_CR15","unstructured":"Centers for Medicare & Medicaid Hospital Outpatient PPS Addendum A and B Updates January 2011. [\n                    http:\/\/www.cms.gov\/HospitalOutpatientPPS\/AU\/list.asp\n                    \n                  ]"},{"key":"1637_CR16","doi-asserted-by":"crossref","unstructured":"Plasmapheresis and acute Guillain-Barr\u00e9 syndrome. The Guillain-Barr\u00e9 syndrome study group. Neurology. 1985, 35: 1096-1104.","DOI":"10.1212\/WNL.35.8.1096"},{"key":"1637_CR17","doi-asserted-by":"crossref","unstructured":"Raphael JC, Chevret S, Hughes RA, Annane D: Plasma exchange for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev. 2002, CD001798-2","DOI":"10.1002\/14651858.CD001798"},{"key":"1637_CR18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/0955-3886(94)90185-6","volume":"15","author":"R Weinstein","year":"1994","unstructured":"Weinstein R: Treatment of Guillain-Barr\u00e9 syndrome: listening carefully to the music before jumping on the bandwagon. Transfus Sci. 1994, 15: 490-495. 10.1016\/0955-3886(94)90185-6.","journal-title":"Transfus Sci"},{"key":"1637_CR19","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1056\/NEJM199209103271117","volume":"327","author":"JC Raphael","year":"1992","unstructured":"Raphael JC, Chastang C, Chevret S, Gajdos P: Intravenous immune globulin versus plasma exchange in Guillain-Barr\u00e9 syndrome. New Engl J Med. 1992, 327: 816.","journal-title":"New Engl J Med"},{"key":"1637_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/CND.0b013e318182b5ce","volume":"10","author":"A Alshekhlee","year":"2008","unstructured":"Alshekhlee A, Hussain Z, Sultan B, Katirji B: Immunotherapy for Guillain-Barr\u00e9 syndrome in the US hospitals. J Clin Neuromuscul Dis. 2008, 10: 4-10. 10.1097\/CND.0b013e318182b5ce.","journal-title":"J Clin Neuromuscul Dis"},{"key":"1637_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1744-9987.2005.00319.x","volume":"9","author":"N Basic-Jukic","year":"2005","unstructured":"Basic-Jukic N, Kes P, Glavas-Boras S, Brunetta B, Bubic-Filipi L, Puretic Z: Complications of therapeutic plasma exchange: Experience with 4857 treatments. Ther Apher Dial. 2005, 9: 391-395. 10.1111\/j.1744-9987.2005.00319.x.","journal-title":"Ther Apher Dial"},{"key":"1637_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jca.2920090102","volume":"9","author":"D Couriel","year":"1994","unstructured":"Couriel D, Weinstein R: Complications of therapeutic plasma exchange: A recent assessment. J Clin Apher. 1994, 9: 1-5. 10.1002\/jca.2920090102.","journal-title":"J Clin Apher"},{"key":"1637_CR23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/jca.20143","volume":"22","author":"D Shemin","year":"2007","unstructured":"Shemin D, Briggs D, Greenan M: Complications of therapeutic plasma exchange: A prospective study of 1,727 procedures. J Clin Apher. 2007, 22: 270-276. 10.1002\/jca.20143.","journal-title":"J Clin Apher"},{"key":"1637_CR24","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1046\/j.1537-2995.1989.29789369679.x","volume":"29","author":"JH Noseworthy","year":"1989","unstructured":"Noseworthy JH, Shumak KH, Vandervoort MK: Long-term use of antecubital veins for plasma exchange. The Canadian Cooperative Multiple Sclerosis Study Group. Transfusion. 1989, 29: 610-613. 10.1046\/j.1537-2995.1989.29789369679.x.","journal-title":"Transfusion"},{"key":"1637_CR25","doi-asserted-by":"publisher","first-page":"V75","DOI":"10.1007\/s00415-006-5013-z","volume":"253","author":"M Wittstock","year":"2006","unstructured":"Wittstock M, Zettl UK: Adverse effects of treatment with intravenous immunoglobulins for neurological diseases. J Neurol. 2006, 253: V75-V79. 10.1007\/s00415-006-5013-z.","journal-title":"J Neurol"},{"key":"1637_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12026-007-0003-5","volume":"38","author":"M Ballow","year":"2007","unstructured":"Ballow M: Safety of IVIG therapy and infusion related adverse events. Immunol Res. 2007, 38: 122-132. 10.1007\/s12026-007-0003-5.","journal-title":"Immunol Res"},{"key":"1637_CR27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","volume":"6","author":"U Katz","year":"2007","unstructured":"Katz U, Achiron A, Sherer Y, Shoenfeld Y: Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007, 6: 257-259. 10.1016\/j.autrev.2006.08.011.","journal-title":"Autoimmun Rev"},{"key":"1637_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.intimp.2005.11.015","volume":"6","author":"DJ Hamrock","year":"2006","unstructured":"Hamrock DJ: Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2006, 6: 535-542. 10.1016\/j.intimp.2005.11.015.","journal-title":"Int Immunopharmacol"},{"key":"1637_CR29","volume-title":"Health Insurance Coverage: Early Release of Estimates from the National Health Interview Survey, 2006","author":"RA Cohen","year":"2007","unstructured":"Cohen RA, Martinez ME: Health Insurance Coverage: Early Release of Estimates from the National Health Interview Survey, 2006. 2007, Hyattsville, MD. National Center for Health Statistics, [\n                    http:\/\/www.cdc.gov\/nchs\/data\/nhis\/earlyrelease\/insur200706.pdf\n                    \n                  ]"},{"key":"1637_CR30","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/ana.410360607","volume":"36","author":"PJ Dyck","year":"1994","unstructured":"Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O'Brien PC: A plasma exchange versus immune globulin trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994, 36: 838-845. 10.1002\/ana.410360607.","journal-title":"Ann Neurol"},{"key":"1637_CR31","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","volume":"41","author":"P Gajdos","year":"1997","unstructured":"Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C: Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol. 1997, 41: 789-796. 10.1002\/ana.410410615.","journal-title":"Ann Neurol"},{"key":"1637_CR32","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","volume":"25","author":"J Ronager","year":"2001","unstructured":"Ronager J, Ravnborg M, Hermansen I, Vorstrup S: Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs. 2001, 25: 967-973. 10.1046\/j.1525-1594.2001.06717.x.","journal-title":"Artif Organs"},{"issue":"Suppl 4","key":"1637_CR33","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.jaci.2006.01.015","volume":"117","author":"JS Orange","year":"2006","unstructured":"Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson RP, Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham-Rundles C: Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma, and Immunology. J Allergy Clin Immunol. 2006, 117 (Suppl 4): 525-553.","journal-title":"J Allergy Clin Immunol"},{"key":"1637_CR34","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jocn.2008.08.033","volume":"16","author":"S Vucic","year":"2009","unstructured":"Vucic S, Kiernan MC, Cornblath DR: Guillain-Barr\u00e9 syndrome: An Update. J Clin Neurosci. 2009, 16: 733-741. 10.1016\/j.jocn.2008.08.033.","journal-title":"J Clin Neurosci"},{"key":"1637_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1002\/(SICI)1098-1101(1999)14:3<107::AID-JCA1>3.0.CO;2-3","volume":"14","author":"S Nagpal","year":"1999","unstructured":"Nagpal S, Benstead T, Shumak K, Rock G, Brown M, Anderson DR: Treatment of Guillain-Barr\u00e9 syndrome: a cost-effectiveness analysis. J Clin Apher. 1999, 14: 107-113. 10.1002\/(SICI)1098-1101(1999)14:3<107::AID-JCA1>3.0.CO;2-3.","journal-title":"J Clin Apher"},{"key":"1637_CR36","unstructured":"1999 National Occupational employment and Wage Estimates 29-1111 Registered Nurses. [\n                    http:\/\/www.bls.gov\/oes\/1999\/oes291111.htm\n                    \n                  ]"},{"key":"1637_CR37","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jocn.2006.03.020","volume":"14","author":"CP Tsai","year":"2007","unstructured":"Tsai CP, Wang KC, Liu CY, Sheng WY, Lee TC: Pharmacoeconomics of therapy for Guillain-Barr\u00e9 syndrome: plasma exchange and intravenous immunoglobulin. J Clin Neurosci. 2007, 14: 625-629. 10.1016\/j.jocn.2006.03.020.","journal-title":"J Clin Neurosci"},{"key":"1637_CR38","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jocn.2008.11.004","volume":"16","author":"EJ Buenz","year":"2009","unstructured":"Buenz EJ: Comment on \"Pharmacoeconomics of therapy for Guillain-Barr\u00e9 syndrome: plasma exchange and intravenous immunoglobulin\". J Clin Neurosci. 2009, 16: 1110-10.1016\/j.jocn.2008.11.004.","journal-title":"J Clin Neurosci"},{"key":"1637_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1212\/01.wnl.0000316393.54258.d1","volume":"71","author":"PD Frenzen","year":"2008","unstructured":"Frenzen PD: Economic cost of Guillain-Barr\u00e9 syndrome in the United States. Neurology. 2008, 71: 21-27. 10.1212\/01.wnl.0000316393.54258.d1.","journal-title":"Neurology"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6963-11-101\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-11-101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-11-101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6963-11-101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T16:52:04Z","timestamp":1581958324000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/1472-6963-11-101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,16]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1637"],"URL":"https:\/\/doi.org\/10.1186\/1472-6963-11-101","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,16]]},"article-number":"101"}}